NasdaqCM - Nasdaq Real Time Price USD

Portage Biotech Inc. (PRTG)

Compare

4.4100

-0.1500

(-3.29%)

At close: January 31 at 4:00:00 PM EST

5.4900

+1.08

+(24.49%)

After hours: 7:59:56 PM EST

Portage Biotech Announces Completion of $2.15 Million Private Financing

DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that it has completed a private placement of $2.15 million from two Portage directors. The 524,390 ordinary shares were sold at $4.10 per share, the Nasdaq official Closing Price on January 22, 2025. Portage intends to use the proceeds from the financing for working capital and other

GlobeNewswire yesterday

PRTG
-3.29%
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc. As CEO, Mr. Mol

GlobeNewswire 25 days ago

PRTG
-3.29%
Top Midday Gainers

Nukkleus (NUKK) said Tuesday it acquired a 51% controlling stake in Star 26 Capital, a defense acqui

Premium
MT Newswires last month

PRTG
-3.29%
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, is pleased to announce that it has entered into a Letter of Intent (“LOI”) with Immunova, LLC, (“Immunova”) a private Connecticut-based biotechnology company. Under the terms of the LOI, Portage and Immunova have agreed to negotiate a definitive o

GlobeNewswire last month

PRTG
-3.29%
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

No impact at this time on the listing of the Company’s Ordinary Shares on NasdaqCompany intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, announced today that it received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) on Dec

GlobeNewswire last month

PRTG
-3.29%
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Exploration and evaluation of strategic alternatives continueWESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended September 30, 2024. “We are continuing to explore multiple strategic alternatives to further unlock shareholder value. Th

GlobeNewswire 2 months ago

PRTG
-3.29%
Portage Biotech's Market Cap Drops To US$4.3m Leaving Insiders With Losses

Insiders who acquired US$1.24m worth of Portage Biotech Inc.'s ( NASDAQ:PRTG ) stock at an average price of US$17.65 in...

Simply Wall St. 2 months ago

PRTG
-3.29%
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update

Exploration and evaluation of strategic alternatives continueWESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended June 30, 2024. “We continue to explore strategic alternatives. These may include finding a partner for one or more of our

GlobeNewswire 5 months ago

PRTG
-3.29%
Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update

Exploration and evaluation of strategic alternatives continuePausing patient enrollment in the ADPORT-601 clinical trial (adenosine 2A and 2B inhibitors)Discontinuing the iNKT clinical trial for PORT-2 WESTPORT, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today announced its financial results for the

GlobeNewswire 5 months ago

PRTG
-3.29%
Portage Biotech Announces 1-for-20 Reverse Stock Split

WESTPORT, Conn., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today announced that the Company’s Board of Directors approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024, Portage’s ordinary shares are expected to begin trading on

GlobeNewswire 5 months ago

PRTG
-3.29%
Converge Technology Solutions Rating, Price Target Left Unchanged by National Bank Following Deconsolidation of Portage CyberTech

Converge Technology Solutions Rating, Price Target Left Unchanged by National Bank Following Deconsolidation of Portage CyberTech

Premium
MT Newswires 6 months ago

PRTG
-3.29%
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

-Adenosine clinical development pausedWESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway. After a review of the Company’s future funding needs for clinical development of its adenosine an

GlobeNewswire 9 months ago

PRTG
-3.29%
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS). Portage was an early INTS investor and during the past few months, Portage has been able to monet

GlobeNewswire 10 months ago

PRTG
-3.29%
INTS
PRTG: Extending the Runway

By John Vandermosten, CFA NASDAQ:PRTG READ THE FULL PRTG RESEARCH REPORT 3Q:24 Financial and Operational Results Since our initiation in January, Portage Biotech Inc. (NASDAQ:PRTG), has reported its third quarter financial and operational results, and continued to progress the Phase Ia/Ib PORT-6 trial. Eight academic center clinical sites are enrolling patients and the Phase Ia dose escalation

Zacks Small Cap Research 10 months ago

PRTG
-3.29%
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Company focused on adenosine platform clinical developmentWESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023. “The Company is focused on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and P

GlobeNewswire 10 months ago

PRTG
-3.29%

Performance overview

Return	PRTG	S&P 500
YTD	-14.20%	+2.26%
1-year	-74.97%	+22.65%
3-year	-97.60%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Portage Biotech Inc. (PRTG)

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Top Midday Gainers

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech's Market Cap Drops To US$4.3m Leaving Insiders With Losses

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update

Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update

Portage Biotech Announces 1-for-20 Reverse Stock Split

Converge Technology Solutions Rating, Price Target Left Unchanged by National Bank Following Deconsolidation of Portage CyberTech

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

PRTG: Extending the Runway

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Performance overview